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Abstract
Background: In people with cystic fibrosis (CF), higher exercise capacity is associated with better health-related
quality of life (HRQoL), reduced risk of hospitalisation for a respiratory infection and survival. Therefore, optimisation
of exercise capacity is an important treatment goal. The Australian and New Zealand clinical practice guidelines
recommend that people with CF complete 30 to 60 min of moderate intensity aerobic exercise on most days of
the week. This recommendation can be difficult to achieve by people with CF because of time constraints, and
intolerable breathlessness and muscle fatigue during continuous exercise. In contrast, a low-volume, high intensity
interval training (HIIT) program may be a more achievable and efficient training method to improve exercise
capacity in people with CF.
Methods: A randomised controlled trial will be undertaken. Forty people with CF (aged ≥15 years) will be
randomly allocated, on a 1:1 ratio, to either the experimental or control group. Regardless of their group
allocation, all participants will be asked to continue with their usual daily treatment for the study duration.
Those in the experimental group will complete 8 weeks of thrice weekly HIIT on a cycle ergometer. Those in
the control group will receive weekly contact with the investigators. The primary outcome of this study is
exercise capacity. Secondary outcomes are HRQoL, exercise self-efficacy, feelings of anxiety, depression and
enjoyment. These outcomes will be recorded at baseline (i.e. prior to randomisation) and following the 8-
week intervention period. The study will also report other outcomes of the HIIT program (cardiovascular responses,
symptom response, post-exercise muscle soreness and tolerance) and behaviour change techniques such as
reinforcement, feedback and goal setting, used during the HIIT program.
Discussion: This study will determine the effects of 8-weeks of supervised, low-volume HIIT, completed on a cycle
ergometer on measures of exercise capacity, HRQoL, exercise self-efficacy, feelings of anxiety, depression and enjoyment.
If effective, this type of training could be an attractive alternative to traditional continuous training because it may be
more achievable and time efficient.
Trial registration: Australian and New Zealand Clinical Trials Registry (ANZCTR):12617001271392 (04/09/2017).
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Background
Cystic fibrosis (CF) is a genetic disease which predom-
inantly affects Caucasians [1]. Several organs are
affected by CF and premature death, primarily due to
respiratory failure, is inevitable [1]. Advancements in
multidisciplinary care over the past 50 years have
resulted in a rise in median life expectancy from 1 year
in 1938 [2, 3], 10 years in 1966, 28 years in 1989 [4] to
now over 40 years of age [5]. These advancements in
multidisciplinary care come at the cost of a high daily
treatment burden. That is, the medical, nutritional and
physiotherapy regimens for people with CF are time
consuming and can take up to 4 h each day [6], which
need to be accommodated with the usual demands of
life, such as work, study and family commitments [7].
Compared to their healthy counterparts, important
markers of exercise capacity are reduced in people
with CF [8, 9]. The cause of such reduction is multifac-
torial and includes decrements in lung function,
peripheral muscle deconditioning which are both likely
to contribute to severe breathlessness during exercise
[8]. Additionally, people with CF may have impaired
cardiac and vascular function [10–12]. In this popula-
tion, higher exercise capacity, for example the peak
rate of oxygen uptake (VO2peak), is associated with bet-
ter health-related quality of life (HRQoL) [13, 14], re-
duced risk of hospitalisation due a respiratory
infection [15] and survival [16, 17]. Given this relation-
ship, improving exercise capacity is an important treat-
ment goal in this population [18].
Markers of exercise capacity can be improved in
people with CF by undertaking ‘traditional’ moderate in-
tensity, continuous, aerobic exercise training [19–22].
While the optimal method of exercise training in this
population requires further investigation [23], the Aus-
tralian and New Zealand clinical practice guidelines rec-
ommend that people with CF complete 30 to 60 min of
moderate intensity exercise on most days of the week
[24]. However, in people with CF, this type of exercise
training is burdensome, adding to the already high daily
treatment burden, and may not be the most appropriate
option due to several factors, including a ‘lack of time’
[25] and intolerable symptoms of breathlessness and
muscle fatigue experienced during continuous exercise
[26]. Furthermore, oxygen desaturation is more likely
during moderate intensity continuous exercise [27], and
this type of training may augment inflammation in this
population compared to interval training [28]. An alter-
native training approach, such as low-volume high inten-
sity interval training (HIIT), may be a more achievable
and efficient method to optimise exercise capacity in this
population [29].
High intensity interval training consists of short pe-
riods of high intensity exercise (‘work’), interrupted
by periods of lower intensity exercise (‘rest’) [30]. The
‘rest’ period allows for partial recovery of symptoms
such as breathlessness and muscle fatigue, and there-
fore offers the opportunity to optimise the training
intensity achieved during the ‘work’ periods [31, 32].
In healthy adults [32] and people with chronic
obstructive pulmonary disease (COPD) [33], HIIT is
well tolerated and offers similar gains in exercise cap-
acity to continuous training, with fewer symptoms of
breathlessness and muscle fatigue [34, 35], and lower
training time [36] or work [37] per session. Addition-
ally, HIIT has been reported to be more enjoyable
than other modes of exercise training [38]. Prelimin-
ary data suggest that HIIT is feasible in people with
CF [26, 27]. However, the effectiveness of low-volume
HIIT to improve exercise capacity in this population
has not been investigated in a randomised controlled
trial (RCT).
The primary aim of this RCT is, in people with CF aged
≥15 years, to determine the effects of an 8-week supervised
low-volume HIIT program on exercise capacity (primary
outcome), and HRQoL, exercise self-efficacy, feelings of
anxiety, depression and enjoyment. As a secondary aim, in
those allocated to receive HIIT, this study will also report
on: (i) the proportion of participants who develop
post-exercise quadriceps femoris muscle soreness each
week during the 8-week HIIT program as well as the sever-
ity of this symptom; (ii) the participant tolerance of the
8-week supervised HIIT program; (iii) the cardiorespiratory
and symptom responses elicited during the HIIT sessions
throughout the 8-week program and; (iv) the behaviour
change techniques (BCTs) employed throughout the pro-
gram. If the HIIT program is shown to be effective at im-
proving exercise capacity, the implementation of such a
time efficient program will result in a lower treatment
burden, compared to undertaking moderate intensity con-
tinuous exercise and therefore may be more readily incor-
porated into the daily routine of people with CF.
Methods
This is a prospective, single-blinded RCT. The study has
been approved by the relevant ethics committees and has
been registered with the Australian and New Zealand
Clinical Trials Registry (ANZCTR) (12617001271392, 04/
09/2017). Participant recruitment will commence in Sep-
tember 2017. The study will be reported in accordance
with the Consolidated Standards of Reporting Trials
(CONSORT) statement [39]. The study flow diagram is
presented in Fig. 1.
Recruitment and consent
Potential participants will be identified and recruited from
scheduled outpatient clinic appointments at the adult (Sir
Charles Gairdner Hospital [SCGH]) and children’s (Perth
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Children’s Hospital ([PCH]) CF centres. Potential par-
ticipants will be provided with an information sheet
summarising the study and will receive a phone call
within 48 h of their clinic visit to discuss their will-
ingness to participate. At the beginning of the first
study visit, written informed consent will be obtained
from participants or assent if the participant is under
18 years of age.
Inclusion and exclusion criteria
Males and females with CF will be invited to partici-
pate in this study if they: (i) are aged ≥15 years and; (ii)
have a body mass index (BMI) > 16 kg/m2. Exclusion
criteria will comprise: (i) current or recent (within the
previous 4 weeks) exacerbation of CF which required
oral or intravenous antibiotics; (ii) a co-morbid condi-
tion that would impact on the ability to undertake a
maximal incremental exercise capacity test; (iii) poorly
controlled diabetes as deemed by their treating endo-
crinologist; (iv) previous lung transplant or current
listing for lung transplantation; (v) participation in ex-
ercise at a moderate intensity two or more times per
week for the previous 3 months and; (vi) the inability
to provide written informed consent due to a cognitive
impairment or being unable to understand English. If a
potential participant has cystic fibrosis-related dia-
betes, they will be included pending approval from the
treating endocrinologist, irrespective of the treatment
they are on.
Randomisation and allocation concealment
Participants will be randomly allocated, on a 1:1 ratio,
to either the experimental or control group. Conceal-
ment of the allocation sequence will be ensured by
using a central randomisation service (the National
Health and Medical Research Council randomisation
service). A minimisation algorithm will be used to strat-
ify for site of recruitment (i.e. SCGH or PCH), spirom-
etry (i.e. mild [FEV1 ≥ 70% predicted], moderate [FEV1
40 to 69% predicted] or severe [FEV1 ≤ 39% predicted])
and the use (or not) of Ivacaftor, which is a medication
that improves lung function, weight, HRQoL and re-
duces the rate of exacerbation [40].
Fig. 1 Study design flow diagram
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Assessment period
Both prior to randomisation (i.e.baseline) and follow-
ing the intervention period (i.e. follow-up), participants
will complete assessments over two non-consecutive
days; assessment day one and assessment day two.
Each assessment visit will last 1.5 h, and both visits will
be completed within 2 weeks. During both the baseline
and follow-up assessments, descriptive variables will
be recorded related to age, gender, height, weight,
genotype and spirometry (Medgraphics USB Spirom-
eter, MCG Diagnostics, Minnesota, USA). Measures
related to the primary aim will be collected in both
groups during the baseline and follow-up assessment.
This will comprise exercise capacity, HRQoL, exercise
self-efficacy, feelings of anxiety, depression and enjoy-
ment. The follow-up assessments of these outcomes
will be completed by an assessor who is blinded to
group allocation. Measures related to the secondary
aim will be collected in the experimental group only
and will comprise post-exercise muscle soreness (mea-
sured weekly), tolerance (measured at every HIIT ses-
sion) and cardiorespiratory and symptom responses to
HIIT (measured at week 1, week 4 and week 8 of the
HIIT program) will be measured throughout the
8-week period. Details of these measurements are
provided below.
Assessment day one
On the first assessment day each participant will
complete a ramp-based cycle ergometry test on an
electronically-braked cycle ergometer (Ergoselect 100;
Ergoline, Bitz, Germany). The test will commence with
1 min of rest, followed by 1 min of unloaded cycling.
Thereafter, a ‘continuous ramp’ protocol will be used
to progressively increase the work rate until the par-
ticipant is unable to continue due to intolerable symp-
toms (i.e. symptom limitation). The magnitude of
change in work rate will be individualised based on the
participant’s age and pre-existing level of fitness (as
subjectively reported by the participant), with the aim
of achieving symptom limitation in 8 to 12 min [41].
Throughout the test, participants will be asked to cycle
at a cadence of 60 rpm. Breath by breath measure-
ments will be collected of minute ventilation, breath-
ing pattern, rate of oxygen consumption (VO2) and
rate of expired carbon dioxide production (VCO2)
(Medgraphics CardioO2; Medical Graphics Corpor-
ation). Measures of heart rate (HR) and oxygen satur-
ation (SpO2) will be continuously monitored and
recorded using a 12 lead electrocardiogram and an ear
probe attached to a pulse oximeter (Ohmeda Biox
3700e ear probe, Colorado, USA), respectively. Blood
pressure will be measured every 2 min using an auto-
mated blood pressure (BP) machine (Tango M2;
Suntech, North Carolina, USA) with a BP cuff con-
nected to the participants’ right arm. Measures of
breathlessness and muscle fatigue will be recorded
each minute using a modified Borg scale [42]. The
peak rate of oxygen uptake (VO2peak) will be defined as
the average VO2 during the final 30 s of the test [43].
Following completion of the ramp-based cycle ergo-
metry test, the participants will be asked to complete
two questionnaires: (i) the Cystic Fibrosis Question-
naire- Revised (CFQ-R) [44, 45] which takes approxi-
mately 15 min to complete and is a valid and reliable
questionnaire for use in people with CF [44, 45], and;
(ii) the Barriers Self-efficacy Scale (BARSE) [46], which
takes approximately 5 min to complete and is a valid
and reliable tool in healthy people [46].
Assessment day two
On a separate, non-consecutive day, the constant work
rate test will be performed in order to establish time to
symptom limitation (Tlim) (primary outcome). This test
will be conducted using identical equipment and measure-
ments as described for the ramp-based cycle-ergometry
test. Participants will be asked to complete a 1-min
warm-up of unloaded cycling after which the work rate
will be increased to 80% of the Wmax [48]. An intensity of
80% of the Wmax has been chosen as this has been dem-
onstrated to be feasible in people with CF [48]. In
addition, at this cycling intensity, more than half of people
with chronic respiratory disease (CF or COPD) achieve a
Tlim of between 8 and 11 min; a test duration which is
most responsive to change following the intervention
period [49, 50]. During the baseline assessment, if a par-
ticipant does not demonstrate signs of symptom limitation
at 10 min, then the test will be terminated and, following
a seated rest of 30 min, the test will be repeated at a
higher intensity [43, 50]. During the follow-up assessment,
the constant work rate test will be completed at the high-
est work rate used during the baseline assessment. In the
follow-up assessment, the constant work rate test will be
terminated at 20 min for participants who do not reach
symptom limitation earlier and Tlim will be recorded as
20 min.
Following completion of the constant work rate exercise
test, participants will be asked to complete three question-
naires; (i) the Alfred Wellness Score for CF (AweScor-
e-CF) [51], which takes approximately 2 min to complete
and is a reliable tool for use in people with CF [51]; (ii) the
Hospital Anxiety and Depression Scale (HADS) [52],
which takes approximately 10 min to complete, is a valid,
reliable and responsive measure and has been widely used
in people with CF [52], and; (iii) the Physical Activity En-
joyment Scale (PACES), which is a valid and reliable tool
previously used in healthy people and takes approximately
5 min to complete [53].
Sawyer et al. BMC Sports Science, Medicine and Rehabilitation           (2018) 10:19 Page 4 of 8
Intervention period
Regardless of group allocation, throughout the duration
of the study, participants will continue usual care. This
includes medication, nutritional support, airway clear-
ance regimens and attendance at a multidisciplinary
outpatient CF clinic, which occur quarterly, or more
frequently if clinically indicated. In both groups, usual
care for each participant will be recorded weekly
throughout the intervention period. To do so, partici-
pants will be asked if there have been any changes to
their treatment in the preceding week.
Experimental group
Participants allocated to the experimental group will be
asked to complete an 8-week cycling-based HIIT pro-
gram. Each training session will involve a 2-min active
‘warm up’ at 15 to 20 W, followed by a 30-s ‘work’
phase and 30-s ‘rest’ period, repeated six times. The
work to rest periods will be followed by a 2-min active
‘cool down’ period at 15 to 20 W. Therefore, the total
training time per session, inclusive of rest periods, will
be 10 min. Each session will be supervised by a physio-
therapist who is trained in the management of people
with CF. To minimise the onset of post-exercise muscle
soreness and optimise adherence, the training program
will commence with a ‘lead in’ phase which will involve
only two sessions of HIIT in weeks 1 and 2. Thereafter,
between weeks 3 and 8, HIIT will be undertaken three
times a week (i.e. total 22 sessions over 8 weeks). The
training intensity will be prescribed using measure-
ments of maximum work rate (Wmax) achieved during
the ramp-based cycle ergometry test completed during
the baseline assessments. Specifically, the first training
session will be prescribed at 60% of Wmax, with the goal
of achieving a training intensity equal to 80% of Wmax
during the fourth training session (i.e. the end of week
2). Thereafter, training intensity will be increased as
rapidly as symptoms of breathlessness and muscle fa-
tigue permit. Training will be completed at one of two
sites, with the participant permitted to choose the site
that is most convenient for them. The model of exer-
cise bike used for the HIIT sessions will be identical
across all training sites (Orbit Eco Generator Interval
Bike OEB2002, Perth, Australia). Only a single partici-
pant will be permitted to use the exercise room on any
day, with stringent hand hygiene and cleaning proce-
dures adhered to at all times to reduce the risk of cross
contamination between participants [54]. The interven-
tion will be conducted and reported in accordance with
the TIDieR checklist [55] and CERT guidelines [56, 57].
If a participant in the experimental group reports the
onset of symptoms indicative of an exacerbation of CF
(i.e. increased sputum volume, changes in the charac-
teristics of sputum, blood present in the sputum,
increased cough, pain from coughing, new wheeze or
increased wheeze, new or increased chest tightness,
shortness of breath or difficulty breathing, increased fa-
tigue or lethargy, fever, loss of appetite or weight, sinus
pain or tenderness) [58], they will be referred to their
respective CF team for medical review. If an exacerba-
tion is diagnosed by the treating CF team, the partici-
pant will be invited to continue participating in HIIT
sessions once deemed to be medically stable by a CF
clinician. Medical stability has been defined as being
afebrile, having resting BP, HR and SpO2 within limits
of the participants’ baseline values and/or deemed
stable by the treating CF clinician. In the event of
missed attendance to HIIT sessions, the training pro-
gram will be extended by a maximum of 2 weeks so
that the participant will have 10 weeks to complete the
22 HIIT sessions.
Measurements related to the secondary aim (collected in
the experimental group only)
Post-exercise muscle soreness Participants in the ex-
perimental group will be asked if they experienced any
post-exercise quadriceps femoris muscle soreness whilst
completing a ‘sit to stand’ 24 h following the first train-
ing session of each week. Those who report experien-
cing post-exercise muscle soreness will be asked to rate
its severity using a Visual Analogue Scale (VAS) [59].
Tolerance The level of participant attendance and com-
pletion of the HIIT sessions will be recorded throughout
the 8-week period. Oxygen saturation (SpO2) at rest and
nadir SpO2 will be recorded during each training session.
Adverse events will be monitored throughout the HIIT
program. These will be categorised as minor, if they are
transient and self-limiting events (i.e. breathlessness
without significant oxygen desaturation [< 4% from the
participant’s pre-exercise SpO2], muscle or general fatigue)
or major events if they require the participant to cease
training during any given session or necessitate medical
assistance (i.e. breathlessness with significant oxygen
desaturation [≥ 4% from the participants pre-exercise
SpO2], pain, vasovagal events or haemoptysis).
Cardiorespiratory and symptom responses During
weeks 1, 4 and 8 of the training period, participants in
the experimental group will be asked to complete one
of two or three (week 3 onwards) HIIT sessions in the
same laboratory used to conduct the ramp-based cycle
ergometry test. During these sessions, measurements
will be collected of minute ventilation, breathing pat-
tern, VO2 and VCO2, HR, SpO2 and BP. Breathlessness
and muscle fatigue will be assessed using the modified
Borg scale [42].
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Behaviour change techniques The HIIT sessions will be
audio recorded over the course of the 8-week program.
The purpose of this will be to allow for qualitative analysis
and reporting of BCTs [60], as recommended by the
CONSORT guidelines [61]. Behaviour change techniques
are defined as the active component of an intervention
that targets a specific behaviour. These techniques can be
used alone, or in combination with another technique. Of
note, to be considered a BCT, the intervention needs to be
observable, able to be replicated, and designed to alter
existing or stimulate new behaviour [60]. Some examples
of BCTs are reinforcement, self-monitoring, feedback,
problem solving, graded tasks and reward. The BCTs will
be reported in accordance with the Taxonomy (v1) by
Michie et al. [60]. All HIIT sessions will be audio recorded,
unless the participant ‘opts-out’. This audio recording
process will also allow for fidelity checking of the sessions
if required by the relevant ethics committee.
Control group
Participants allocated to the control group will be
contacted once a week by a physiotherapist to discuss
changes to their symptoms, healthcare utilisation and
participation in exercise over the preceding week. Par-
ticipants will be allowed to choose the way in which
this contact is made; phone calls, texts or emails. If a
participant allocated to the control group reports any
symptoms that are suggestive of an exacerbation, they
will be referred to the CF team for medical review.
Statistical analyses
The results of this study will be analysed according to
the intention-to-treat principle using Statistical Pack-
age for the Social Sciences (SPSS) (Version 22, SPSS,
Chicago, IL, USA). The distribution of data will be
checked using frequency histograms. A p value of <
0.05 will be considered statistically significant. Audio
recording of the HIIT sessions will be analysed using
NVivo software.
To address differences between the experimental and
control group, between-group differences in all out-
comes (e.g. Tlim, VO2peak, HRQoL, exercise self-efficacy,
feelings of anxiety, depression and enjoyment) will be
assessed using linear mixed models. Baseline measures
will be used as a covariate and group allocations will be
used as a fixed factor. Total in work done (i.e. training
dose) will be considered in the analyses by entering this
parameter as a random factor in the mixed effects
model. To address the proportion of participants who
develop post-exercise muscle soreness, the severity of
post-exercise muscle soreness in those who develop it
over the 8 week intervention period and tolerance of
the HIIT program, descriptive statistics, such as fre-
quency, mean and standard deviation (SD) or median
and interquartile range will be used. To explore differ-
ences in measures of cardiorespiratory and symptom
responses throughout the HIIT program, an analysis of
variance (parametric) or a Friedman’s test (non-para-
metric data) will be used.
Sample size calculations
Constant power tests have been widely used to demon-
strate increases in exercise capacity following a period
of exercise training (i.e. pulmonary rehabilitation) [43,
47], are also more likely to reflect performance of ac-
tivities of daily living [62], as they are performed at a
moderate intensity, compared to tests of peak exercise
capacity [22, 43] and when conducted at 80% of the
Wmax are demonstrated to be highly repeatable in
people with CF [63]. For these reasons, the sample size
calculation for this study has been based on the mea-
surements of Tlim during a constant work rate test,
conducted at 80% of Wmax [43]. There is limited infor-
mation pertaining to the minimal clinically important
difference (MCID) for the Tlim in people with CF.
However, in people with COPD, the MCID for Tlim
during a constant work rate test has been proposed to
be 100 s [43]. In order to detect a between-group dif-
ference of 100 s (MCID for Tlim in COPD), with a SD
of 99 s (largest of the 2 SDs reported for Tlim in a CF
population that will be similar to that recruited in the
study described in this proposal [48]) (α = 0.05 and 1-β
= 0.8) a sample size of 16 per group (n = 32 in total) is
required. This sample size has been inflated by 20% to
account for possible loss to follow-up. Therefore, the
recruitment target for this study will be 40.
Discussion
This study will be the first RCT to evaluate the effects
of HIIT on exercise capacity, HRQoL, exercise
self-efficacy, feelings of anxiety, depression and enjoy-
ment in people with CF. If 30 min of HIIT (i.e. three
10 min sessions) per week is demonstrated to increase
exercise capacity, HRQoL, exercise self-efficacy and en-
joyment, it will represent a more achievable and effi-
cient method of exercise and thereby will overcome the
barrier of ‘lack of time’ [25]. This study will create an
initial, yet strong evidence base for HIIT in people with
CF and has the ability to influence clinical practice.
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